Asthma Biologic Injection Pain

A multicenter observational study published online on October 5, 2026, analyzed injection pain in 122 patients receiving biologic treatment for asthma. On a 0 to 10 visual analog scale, mean pain scores were 3.00 during needle insertion and 3.28 during injection, and higher scores were associated with greater treatment aversion, also measured as a score. Causation was not tested. The study does not show that pain caused anyone to stop treatment.^[1]

The study also included 27 patients with diabetes receiving tirzepatide as a reference group. Tirzepatide was a comparator for adjusted pain scores, not an asthma treatment in this paper. The abstract reports no significant adjusted difference in pain across the asthma biologics and tirzepatide.^[1]

How the study measured pain

Matsumoto and colleagues enrolled patients receiving asthma biologics between May 2025 and March 2026. Participants rated three separate outcomes from 0 to 10: pain when the needle entered the skin, pain while the medicine was injected, and aversion to treatment that they attributed to injection-related pain. Keeping insertion pain and injection pain separate matters because they may have different sources and different associations.^[1]

The investigators evaluated relationships between clinical factors, both pain scores and the treatment-aversion score. They also assessed local pressure and cooling at the injection site. PubMed classifies the report as a journal article, and the paper itself describes the design as multicenter and observational. There was no randomized treatment assignment described in the abstract.^[1][2]

A visual analog scale turns a personal sensation into a number that researchers can compare. It does not make pain fully objective, and a mean near 3 does not mean every participant had mild pain. The reported standard deviations were 2.60 for insertion pain and 2.91 for injection pain, showing wide variation around both averages.^[1]

Pain tracked with treatment aversion

Both pain measures retained independent associations with the log-transformed treatment-aversion score in the study's regression models. For insertion pain, the unstandardized coefficient was 0.08, with a 95% confidence interval from 0.03 to 0.12. For injection pain, the coefficient was 0.07, with a 95% confidence interval from 0.03 to 0.11.^[1]

Those coefficients describe movement in a transformed aversion score within this dataset; they are not percentages, discontinuation rates or estimates of how many patients refused their next dose. No persistence data were reported. The abstract gives no count of missed injections or treatment discontinuations, so describing the result as treatment dropout would go beyond what the researchers measured.^[1]

Different characteristics were associated with the two pain measures: anxiety and injection in the arm with insertion pain, and younger age and female sex with injection pain. These were statistical relationships in the enrolled group. The model establishes no causal pathway from age, sex, anxiety or injection location to the pain differences.^[1]

What the tirzepatide comparison shows

The 27-person tirzepatide reference group gives the analysis a comparison with another injected medicine. After adjustment, pain scores did not differ significantly across the asthma biologics and tirzepatide. A non-significant difference does not prove that the products feel identical. The reference group was small, had diabetes and was outside the severe-asthma treatment population.^[1]

The paper therefore cannot support a general claim about peptide injections or self-injection. It studied named clinical treatment groups under its own protocol. The tirzepatide regulation overview covers the medicine's separate approved uses and jurisdictional status; none of that changes its limited role as a reference group here.^[1]

Cooling is a signal, not a protocol

The abstract reports that injection-site cooling significantly reduced both insertion and injection pain, yet it provides no cooling method, duration, group sizes, effect estimates or confidence intervals. Randomization was not described. Without those details, readers cannot judge the size of the difference or rule out selection and expectation effects.^[1]

Local pressure was among the approaches evaluated, but the abstract does not report a significant pain result for pressure. Silence in an abstract is not evidence that an approach failed. It means the accessible summary does not give enough information to make that claim. The cooling result is best treated as an observational signal that needs the full methods and a controlled test before it becomes a clinical protocol.^[1]

This article does not provide instructions for changing injection technique or applying cooling. Biologic products differ in device, formulation, storage requirements and administration setting. Patients troubled by pain or becoming reluctant to continue treatment should raise that problem with the asthma team managing the biologic rather than changing administration on their own.

What we do not know yet

The available abstract does not name the number of centers, list enrollment by each biologic or report how many patients used cooling. Longitudinal follow-up was not reported. We also cannot tell whether higher aversion scores predicted missed doses or later discontinuation, which limits conclusions about persistence and differences among individual biologic products.^[1]

The study puts a measurable number on an often underreported treatment burden: injection pain. Its clearest finding is the association between higher pain and higher treatment-aversion scores in this sample. Whether reducing pain improves long-term persistence remains unanswered by this observational analysis.^[1]

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.